Nogapendekin alfa inbakicept

Nogapendekin alfa inbakicept
Combination of
Nogapendekin alfahuman IL-15N72D variant
Inbakiceptinterleukin-15 receptor agonist
Clinical data
Trade namesAnktiva
Other namesALT-803, N-803, nogapendekin alfa inbakicept-pmln
AHFS/Drugs.comMonograph
MedlinePlusa624034
License data
Routes of
administration		Intravesical
ATC code
Legal status
Legal status
Identifiers
PubChem SID
KEGG

Nogapendekin alfa inbakicept, sold under the brand name Anktiva, is a fixed-dose combination medication used for the treatment of bladder cancer. It is an interleukin-15 receptor agonist. It is given in combination with Bacillus Calmette-Guérin (BCG) via intravesical drug delivery. It contains nogapendekin alfa, a human IL-15(N72D) variant, which is more potent than regular IL-15; and inbakicept, an interleukin 15 receptor subunit alpha agonist.

The most common adverse reactions include increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills, and pyrexia.

Nogapendekin alfa inbakicept was approved for medical use in the United States in April 2024. The US Food and Drug Administration considers it to be a first-in-class medication.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.